Seroinfection of Antibodies to , Parvovirus B19, , and HIV in a Pregnant Attending a Medical Center in Northern Peru.

Introduction: Transplacental infections are frequent, especially in developing countries, where limited screening is performed to find infectious agents in the pregnant population. We aim to determine the clinical and epidemiological characteristics and seroinfection of antibodies against , parvovirus B19, , and HIV in pregnant women who attended the Motupe Health Center in Lambayeque, Peru during July-August 2018.

Methods: A descriptive cross-sectional study was conducted in 179 pregnant women interviewed with a standardized questionnaire.

'Staying alive' with antiretroviral therapy: a grounded theory study of people living with HIV in Peru.

Background: To achieve an optimal quality of life through chronic disease management, people living with HIV (PLHIV) must adhere to antiretroviral therapy (ART). ART has been available throughout Peru since 2004 without cost in all regions; yet only 60% (43 200) of PLHIV receive ART and 32% are virally suppressed. Despite the low adherence, little is known about the experience of PLHIV with ART adherence in the context of Latin America.

Faculty Attitudes About Caring for People Living With HIV/AIDS: A Comparative Study.

Background: People living with HIV/AIDS (PLHIV) experience stigma and discrimination. Negative attitudes of nursing faculty about caring for PLHIV can adversely affect student perceptions and their nursing care. The study purpose was to describe nursing faculty attitudes and beliefs about caring for PLHIV.

Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study.

Background: There are approximately 72,000 people living with HIV/AIDS (PLHIV) in Peru. Non-adherence to antiretroviral therapy (ART) is the most important factor for therapeutic failure and the development of resistance. Peru has achieved moderate progress in meeting the 90-90-90 targets, but only 60% of PLHIV receiving ART are virally suppressed.